The present study is a randomized, open label, parallel design, controlled clinical study to evaluate the effects of yogic intervention on pulmonary functions, clinical symptoms, oxidative stress markers, inflammation & immunity markers and health status parameters, in patients of COPD. COPD is a chronic inflammatory disorder with associated immunological changes, hence markers of inflammation, immunity and oxidative stress will be assessed in both controls as well as yoga exposed groups (both groups will be given Fixed dose inhaler and SOS L-Salbutamol treatment for COPD). Research methodology is as per ICH-GCP guidelines and protocol has been approved by the Institutional Ethical Committee. In the area of monitoring COPD, FeNO correlates with symptom frequency and bronchodilator use, therefore, in the present study FeNO will be used to predict the response of COPD patients to yogic intervention. The BODE index, is a multidimensional scoring system and capacity index used to test patients who have been diagnosed with COPD and to predict long-term outcomes for them. The index uses four factors (Body-mass, Obstruction, Dyspnea, and Exercise) to predict risk of death from the disease. Isoprostanes are prostaglandin analogs produced by free radical-catalyzed peroxidation of arachidonic acid. 8-isoprostane is useful in the measurement of oxidative stress in lungs, systemic oxidative stress.  In addition to these, markers of inflammation and immunity viz. osteoprotogerin, CC-16, TNF-α, will be measured in patients of COPD. This will be correlated with the blood cells counts i.e. neutrophil-lymphocyte ratio, which play an important role in the early and late phase of COPD. Finally, the effects of yogic intervention on quality of life parameters will be assessed by using St. George’s Respiratory Questionnaire for COPD patients (SGRQ-C).